Navigation Links
Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
Date:2/11/2009

Ferring Pharmaceuticals and Ferring Research Institute Introduce New Research Base and First Molecule Discovered by the Company in San Diego

SAN DIEGO, Feb. 11 /PRNewswire/ -- Leading global biopharmaceutical company, Ferring Pharmaceuticals, and its affiliate Ferring Research Institute have opened a new and expanded, 38,000-square-foot facility located in Sorrento Valley, San Diego that will be dedicated to further development of peptide research and therapeutics.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090211/LA63509)

The new facility was introduced at an event yesterday attended by global executives and top U.S. academic and research collaborators. They included: Nobel Laureate and Interim President for The Salk Institute, Professor Roger Guillemin; Chair and Professor of Medicine, Department of Medicine at Columbia University, Professor Donald Landry; Dean and Professor of Physiology and Medicine at Tufts University School of Medicine, Professor Michael Rosenblatt; representatives from the City of San Diego; and, members of the local biotech community.

The occasion also marked recognition for the recent approval by the U.S. Food and Drug Administration (FDA) of degarelix, a new prostate cancer drug for the treatment of patients with advanced hormone-dependent prostate cancer. Degarelix is the first peptide new chemical entity (NCE) discovered by Ferring Research Institute in San Diego and developed globally by Ferring Pharmaceuticals. Ferring is preparing to launch degarelix in the U.S. in the first quarter of 2009.

Ferring is a privately held global biopharmaceutical company focused on the discovery, development and marketing of biologics, peptides and proteins. The company's research is dedicated to three core therapeutic areas--Infertility, Urology and Gastroe
'/>"/>

SOURCE Ferring Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Cytokinetics, Incorporated (Nasdaq: ... February 28 with patients and health care advocates in ... Rare Disease Day®. Rare Disease Day is dedicated ... attention to the special challenges faced by patients with ... “Cytokinetics is proud to stand alongside patients and caregivers ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Executive Officer of Regulus, will present a company overview ... Healthcare Conference on Wednesday, March 4, 2015 at 9:20 ... Boston Marriott Copley Place.  The presentation ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... (NASDAQ: CPHD ) today announced that, together ... Jersey (UMDNJ), it has received a grant from the ... amplification methods for highly-sensitive detection of bloodstream bacteria using ... The $1.3 million grant is for the first year ...
... 19, 2012   Organovo Holdings, Inc. (OTCQB: ONVO) ... $15.2 million private placement. At the final closing, the ... sale of 6.9 million Units, at a price of ... approximately 43.7 million shares of common stock issued and ...
... of the world,s leading environmental scholars are sounding the alarm ... environmental institutions into a more coherent and robust planetary stewardship ... changes to the Earth,s subsystems. University of ... of a paper which appears in Science on ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3Scholars call for global governance overhaul to ensure Earth's sustainability 2
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... COLUMBIA, Mo. Millions of post-menopausal women use hormone ... associated with menopause. In a recent University of Missouri ... in HRT, a synthetic progestin, could be a major ... the researchers have compelling evidence that using an antibody ...
... What: Challenges and Promise of ... research in regenerative medicine using stem cells. The opening ... cell therapy. This will be followed by four plenary ... of neurological, cardiac, musculoskeletal, and metabolic diseases and disorders. ...
... Will April be the cruelest month? , ... are eerily reminiscent of 1993 and 1994, back-to-back years of serious ... of economic damage, damaging and destroying more than 50,000 homes and ... Parallels this year include abnormally high levels ...
Cached Biology News:MU researcher links hormone replacement therapy to breast cancer 2Challenges and promise of cell-based therapies 2Geologist decries floodplain development 2Geologist decries floodplain development 3
...
Homo sapiens MEP50 protein, mRNA...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: